{"id":51328,"date":"2020-12-16T23:00:00","date_gmt":"2020-12-16T23:00:00","guid":{"rendered":"https:\/\/tax.konradin-online.de\/?p=51328"},"modified":"2020-12-16T23:00:00","modified_gmt":"2020-12-16T23:00:00","slug":"bat-impfstoff-in-entscheidender-phase","status":"publish","type":"post","link":"https:\/\/tax.konradin-online.de\/?p=51328","title":{"rendered":"BAT-Impfstoff in entscheidender Phase"},"content":{"rendered":"<p><strong>LONDON \/\/<\/strong> Der Corona-Impfstoffkandidat von British American Tobacco (BAT) erh\u00e4lt die US-Zulassung f\u00fcr Studien am Menschen, teilte der Hersteller mit. Erste Ergebnisse werden voraussichtlich Mitte 2021 vorliegen. <\/p>\n<p><strong>Wichtiger Meilenstein<\/strong><br \/>\n\u201eDer Einstieg in Studien am Menschen (\u2026) ist ein wichtiger Meilenstein\u201c, sagte David O\u2019Reilly, Direktor f\u00fcr wissenschaftliche Forschung bei BAT. Der Impfstoff wird von Kentucky Bio&#8201;Processing entwickelt.<\/p>\n<p><i>red<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LONDON \/\/ Der Corona-Impfstoffkandidat von British American Tobacco (BAT) erh\u00e4lt die US-Zulassung f\u00fcr Studien am Menschen, teilte der Hersteller mit. Erste Ergebnisse werden voraussichtlich Mitte 2021 vorliegen. Wichtiger Meilenstein \u201eDer Einstieg in Studien am Menschen (\u2026) ist ein wichtiger Meilenstein\u201c, sagte David O\u2019Reilly, Direktor f\u00fcr wissenschaftliche Forschung bei BAT. Der Impfstoff wird von Kentucky Bio&#8201;Processing [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[53355,54616,52701,59111,61724,59371],"class_list":["post-51328","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-british-american-tobacco","tag-corona","tag-e","tag-impfstoff","tag-kentucky-bioprocessing","tag-studien-am-menschen"],"acf":[],"_links":{"self":[{"href":"https:\/\/tax.konradin-online.de\/index.php?rest_route=\/wp\/v2\/posts\/51328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tax.konradin-online.de\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tax.konradin-online.de\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tax.konradin-online.de\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tax.konradin-online.de\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51328"}],"version-history":[{"count":0,"href":"https:\/\/tax.konradin-online.de\/index.php?rest_route=\/wp\/v2\/posts\/51328\/revisions"}],"wp:attachment":[{"href":"https:\/\/tax.konradin-online.de\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tax.konradin-online.de\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tax.konradin-online.de\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}